Basic Information
RNALocate ID: RLID:11002771
RNA Symbol: hsa-miR-429
Localization: Exosome
RNA Information
RNA Name: hsa-miR-429
RNA ID: miRBase:MIMAT0001536
RNA Category: miRNA
Species: Homo sapiens
Sequence:
Localization Information
PubMed ID: 23663360
Tissue/Cell Line: Plasma
Method: Next-generation RNA sequencing
Description: Because the abundance of most miRNAs is low in the exosomes, we defined detectable miRNAs as those that had at least one sequence per million mappable miRNA reads. Accordingly, we detected a total of 593 known miRNAs in the 14 libraries. In each individual library, the number of detectable known miRNAs varied from 380 to 474 with an average of 419 [see Additional file 2]. Data are collected from Additional file 2: Read counts of the miRNAs detected in the 14 libraries (normalized to read number per million mappable miRNA seqeuences).
Other Subcellular Localization
RNALocate ID Localization Tissue/Cell line PubMed ID
RLID:11002768 Exosome Serum 18589210
RLID:11002769 Exosome Breast cancer cell line (MCF-7) 20976003
RLID:11002770 Exosome Brain tissue 23382797
RLID-D:11000139 Exosome Breast milk|Colon tissue|Seminal fluid|Tongue tissue
RLID-D:11000452 Microvesicle Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells
ncRNA Disease Information
Resource RNA Symbol Disease Link
MNDR hsa-mir-429 Oral squamous cell carcinoma MNDR-E-MI-49322
MNDR hsa-miR-429 Oral squamous cell carcinoma MNDR-E-MI-49323
MNDR hsa-miR-429 Large cell neuroendocrine cancer MNDR-E-MI-49324
MNDR hsa-miR-429 High-grade serous ovarian carcinoma MNDR-E-MI-49325
MNDR hsa-miR-429 Uterine corpus endometrial carcinoma MNDR-E-MI-49326
MNDR hsa-mir-429 Immunoglobulin a deficiency MNDR-E-MI-49327
MNDR hsa-mir-429 Non-hodgkin lymphoma somatic MNDR-E-MI-49328
MNDR hsa-miR-429 Estrogen-receptor positive breast cancer MNDR-E-MI-49329
MNDR hsa-miR-429 Estrogen-receptor negative breast cancer MNDR-E-MI-49330
MNDR hsa-miR-429 Progesterone-receptor positive breast cancer MNDR-E-MI-49331
MNDR hsa-miR-429 Progesterone-receptor negative breast cancer MNDR-E-MI-49332
MNDR hsa-miR-429 Her2-receptor positive breast cancer MNDR-E-MI-49333
MNDR hsa-miR-429 Breast cancer luminal MNDR-E-MI-49334
MNDR hsa-mir-429 Colorectal carcinoma MNDR-E-MI-49335
MNDR hsa-mir-429 Fatty liver non-alcoholic MNDR-E-MI-49336
MNDR hsa-mir-429 Prostate cancer MNDR-E-MI-49337
MNDR hsa-mir-429 Leukemia/lymphoma chronic b-cell MNDR-E-MI-49338
MNDR hsa-miR-429 Hirschsprung disease MNDR-E-MI-49339
MNDR hsa-mir-429 Gastric cancer MNDR-E-MI-49340
MNDR hsa-miR-429 Gastric cancer MNDR-E-MI-49341
MNDR hsa-miR-429 Alzheimer disease MNDR-E-MI-49342
MNDR hsa-mir-429 Bladder cancer MNDR-E-MI-49343
MNDR hsa-miR-429 Bladder cancer MNDR-E-MI-49344
MNDR hsa-mir-429 Carcinoma esophageal MNDR-E-MI-49345
MNDR hsa-miR-429 Gilles de la tourette syndrome MNDR-E-MI-49346
MNDR hsa-mir-429 Nephrosclerosis MNDR-E-MI-49347
MNDR hsa-mir-429 Cardiomyopathy dilated MNDR-E-MI-49348
MNDR hsa-miR-429 Lung cancer MNDR-E-MI-49349
MNDR hsa-mir-429 Lung cancer MNDR-E-MI-49350
MNDR hsa-mir-429 Endometrial cancer MNDR-E-MI-49351
MNDR hsa-miR-429 Endometrial cancer MNDR-E-MI-49352
MNDR hsa-mir-429 Azoospermia MNDR-E-MI-49353
MNDR hsa-miR-429 Parkinson disease MNDR-E-MI-49354
MNDR hsa-miR-429 Machado-joseph disease MNDR-E-MI-49355
MNDR hsa-miR-429 Basal-like breast cancer MNDR-E-MI-49356
MNDR hsa-mir-429 Breast cancer MNDR-E-MI-49357
MNDR hsa-mir-429 Cancer MNDR-E-MI-49358
MNDR hsa-miR-429 Cancer MNDR-E-MI-49359
MNDR hsa-miR-429 Thyroid cancer MNDR-E-MI-49360
MNDR hsa-miR-429 Pituitary neoplasms MNDR-E-MI-49361
MNDR hsa-mir-429 Pancreatic cancer MNDR-E-MI-49362
MNDR hsa-miR-429 Pancreatic cancer MNDR-E-MI-49363
MNDR hsa-mir-429 Malignant melanoma MNDR-E-MI-49364
MNDR hsa-miR-429 Melanoma MNDR-E-MI-49365
MNDR hsa-miR-429 Rectum adenocarcinoma MNDR-E-MI-49366
MNDR hsa-mir-429 Nephroblastoma MNDR-E-MI-49367
MNDR hsa-miR-429 Nephroblastoma MNDR-E-MI-49368
MNDR hsa-miR-429 Colon cancer MNDR-E-MI-49369
MNDR hsa-mir-429 Colon cancer MNDR-E-MI-49370
MNDR hsa-miR-429 Colon adenocarcinoma MNDR-E-MI-49371
MNDR hsa-mir-429 Ovarian cancer MNDR-E-MI-49372
MNDR hsa-miR-429 Ovarian cancer MNDR-E-MI-49373
MNDR hsa-mir-429 Adenocarcinoma endometrial MNDR-E-MI-49374
MNDR hsa-miR-429 Endometrial endometrioid carcinoma MNDR-E-MI-49375
MNDR hsa-mir-429 Endometriosis MNDR-E-MI-49376
MNDR hsa-mir-429 Glomerulonephritis MNDR-E-MI-49377
MNDR hsa-mir-429 Iga glomerulonephritis MNDR-E-MI-49378
MNDR hsa-mir-429 Adenocarcinoma MNDR-E-MI-49379
MNDR hsa-miR-429 Carcinoma ductal breast MNDR-E-MI-49380
MNDR hsa-mir-429 Glioblastoma MNDR-E-MI-49381
MNDR hsa-mir-429 Astrocytoma MNDR-E-MI-49382
MNDR hsa-mir-429 Glioma MNDR-E-MI-49383
MNDR hsa-miR-429 Malignant glioma MNDR-E-MI-49384
MNDR hsa-miR-429 Temporal lobe epilepsy MNDR-E-MI-49385
MNDR hsa-mir-429 Osteosarcoma MNDR-E-MI-49386
MNDR hsa-mir-429 Mesenchymal cancer MNDR-E-MI-49387
MNDR hsa-miR-429 Pediatric osteosarcoma MNDR-E-MI-49388
MNDR hsa-miR-429 Liposarcoma MNDR-E-MI-49389
MNDR hsa-miR-429 Breast carcinoma MNDR-E-MI-49390
MNDR hsa-mir-429 Adenocarcinoma pancreatic ductal MNDR-E-MI-49391
MNDR hsa-miR-429 Liver cancer MNDR-E-MI-49392
MNDR hsa-mir-429 Liver neoplasms MNDR-E-MI-49393
MNDR hsa-miR-429 Cervical adenocarcinoma MNDR-E-MI-49394
MNDR hsa-miR-429 Gastric adenocarcinoma MNDR-E-MI-49395
MNDR hsa-miR-429 Cervical squamous cell carcinoma MNDR-E-MI-49396
MNDR hsa-miR-429 Pituitary adenoma MNDR-E-MI-49397
MNDR hsa-miR-429 Lung squamous cell carcinoma MNDR-E-MI-49398
MNDR hsa-mir-429 Carcinoma lung non-small-cell MNDR-E-MI-49399
MNDR hsa-miR-429 Carcinoma lung non-small-cell MNDR-E-MI-49400
MNDR hsa-mir-429 Lung adenocarcinoma MNDR-E-MI-49401
MNDR hsa-miR-429 Lung adenocarcinoma MNDR-E-MI-49402
MNDR hsa-miR-429 Thyroid carcinoma MNDR-E-MI-49403
MNDR hsa-miR-429 Papillary thyroid cancer MNDR-E-MI-49404
MNDR hsa-miR-429 Ovarian carcinoma MNDR-E-MI-49405
MNDR hsa-miR-429 Bladder urothelial carcinoma MNDR-E-MI-49406
MNDR hsa-mir-429 Cervical cancer MNDR-E-MI-49407
MNDR hsa-mir-429 Carcinoma renal cell MNDR-E-MI-49408
MNDR hsa-miR-429 Carcinoma renal cell MNDR-E-MI-49409
MNDR hsa-miR-429 Kidney renal papillary cell carcinoma MNDR-E-MI-49410
MNDR hsa-miR-429 Clear cell renal cell carcinoma MNDR-E-MI-49411
MNDR hsa-miR-429 Biliary tract cancer MNDR-E-MI-49412
MNDR hsa-miR-429 Intrahepatic cholangiocarcinoma MNDR-E-MI-49413
MNDR hsa-miR-429 Cholangiocarcinoma MNDR-E-MI-49414
MNDR hsa-miR-429 Esophageal cancer MNDR-E-MI-49415
MNDR hsa-mir-429 Carcinoma ehrlich tumor MNDR-E-MI-49416
MNDR hsa-miR-429 Lung small cell carcinoma MNDR-E-MI-49417
MNDR hsa-miR-429 Gastric carcinoma MNDR-E-MI-49418
MNDR hsa-miR-429 Testicular germ cell cancer MNDR-E-MI-49419
MNDR hsa-mir-429 Heart failure MNDR-E-MI-49420
MNDR hsa-miR-429 Breast invasive carcinoma MNDR-E-MI-49421
MNDR hsa-mir-429 Carcinoma hepatocellular MNDR-E-MI-49422
MNDR hsa-miR-429 Hepatocellular carcinoma MNDR-E-MI-49423
MNDR hsa-miR-429 Retinoblastoma MNDR-E-MI-49424
MNDR hsa-mir-429 Leukemia chronic myeloid MNDR-E-MI-49425
MNDR hsa-miR-429 Ulcerative colitis MNDR-E-MI-49426
MNDR hsa-mir-429 Mouth neoplasms MNDR-E-MI-49427
MNDR hsa-miR-429 Crohn disease MNDR-E-MI-49428
MNDR hsa-miR-429 Tonsil cancer MNDR-E-MI-49429
MNDR hsa-mir-429 Systemic lupus erythematosus MNDR-E-MI-49430
MNDR hsa-mir-429 Leukemia acute myeloid MNDR-E-MI-49431
MNDR hsa-mir-429 Barrett's esophagus MNDR-E-MI-49432
MNDR hsa-mir-429 Colorectal cancer MNDR-E-MI-49433
MNDR hsa-miR-429 Colorectal cancer MNDR-E-MI-49434
MNDR hsa-miR-429 Nasopharynx carcinoma MNDR-E-MI-49435
MNDR hsa-miR-429 Ovarian epithelial cancer MNDR-E-MI-49436
MNDR hsa-mir-429 Helplessness learned MNDR-E-MI-49437
MNDR hsa-miR-429 Nasopharyngeal cancer MNDR-E-MI-49438
MNDR hsa-mir-429 Myocardial ischemia MNDR-E-MI-49439
MNDR hsa-miR-429 Breast cancer her3+ negative MNDR-E-MI-49440
MNDR hsa-miR-429 Solid-pseudopapillary neoplasm of pancreas MNDR-E-MI-49441
RNA Interaction Information
Resource RNA Symbol Species Link RNALocate ID
RNAInter BAP1 Homo sapiens RR00211603
TOP